Free Newsletter
Celebs lose cachet as drug marketers
Celebs may help sell magazines but do they really help market drugs? In the wake of Robert Jarvik's public downfall from Pfizer's pitchman-pedestal, advertising experts are wondering. Famous folk do generate interest, but maybe meds shouldn't be sold using the same techniques used to hawk detergent.
Consider the fact that the Jarvik controversy revolved around his qualifications to recommend Lipitor, a cholesterol med. Inventor of the artificial heart, Jarvik had never practiced medicine. Critics say that more effective pitches come from famous people who are actual patients, such as Sally Field--who was diagnosed with osteoporosis in 2005--promoting Roche and GlaxoSmithKline's Boniva.
Either way, though, celebrities tend to distract from the ad message--and in drug ads, the rapidly spoken voice-over of side effects is, for safety's sake, an important set of info that needs to be conveyed. That's one reason why Big Pharma has backed off from celebrities and turned to animated bees and Abraham Lincoln instead. Expect more backing off, experts said. "I think the latest round of concern is going to cause a lot of agencies to think twice," one ad exec predicted.
- check out the article in the Boston Globe
Related Articles:
Pfizer yanks Lipitor ads starring Jarvik. Report
Drug ads challenge reputation of inventor. Report
Lunesta moth tops memorable drug ads. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: